NCT02906709View on ClinicalTrials.gov

Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)

PHASE4CompletedINTERVENTIONAL

Enrollment

184

Participants

Timeline

Start Date

October 17, 2016

Primary Completion Date

August 21, 2018

Study Completion Date

August 21, 2018

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Omarigliptin

Omarigliptin, 25 mg orally once weekly

DRUG

Placebo

Placebo to omarigliptin orally once weekly

BIOLOGICAL

Insulin

Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02906709 - Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039) | Biotech Hunter | Biotech Hunter